Fig. 1
a Scheme depicting synchronization and controlled ovarian stimulation protocol used in the study. See text for details. CIDR: intravaginal P4 control internal drug release device, PGF2α: prostaglandin F2α, FSH: follicle stimulating hormone, GnRH: gonadotropin releasing hormone, OVX: ovariectomy, replac.: replacement, US: transrectal ultrasonography. Grey and black arrows indicate time of GnRH antagonist and FSH administration, respectively. b Mean (± SEM) number of 2-3 mm (top panel) and 4-6 mm (bottom panel) before GnRH antagonist (PreGnRHa), after GnRH antagonist (PostGnRHa), before the 3rd and 6th FSH doses (FSH3 and FSH6, respectively), and ovariectomy (OVX) in control (white bars), T (filled bars), T + F (dotted bars), and T + R (stripped dars) females. See Fig. 1 for synchronization and controlled ovarian stimulation protocol and text for details of prenatal/postnatal treatment details. F: flutamide; R: rosiglitazone; n.s.: not significant; * P < 0.01, ** P < 0.001